Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOYAGE: VK2809 in NASH with Fibrosis
NCT04173065Phase 2Completed
- Sponsor
- Viking Therapeutics
- Start
- Nov 2019
- Primary completion
- May 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of VK2809 in Nonalcoholic steatohepatitis (NASH), sponsored by Viking Therapeutics. Started Nov 2019; status: completed.
02
Drugs
VK2809
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04173065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173065.